YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Shares of Denali Therapeutics, Inc. DNLI have gained 33.1% in the last three months compared with the industry's growth of 7.4%. The stock has outperformed the sector and the S&P 500 Index during this time frame. DNLI Outperforms Industry,…
Biogen BIIB stock has risen 9% in a month. A key reason for the stock price increase was Biogen's robust second-quarter 2026 results, as it beat estimates for both earnings and sales. While earnings declined 34% year over year due to deal-…
By Mike Sheikh Parkinson's Disease has challenged drug developers for generations, but Jupiter Neurosciences (NASDAQ: JUNS) is betting that a streamlined clinical plan can break the stalemate. The market isn't recognizing the story yet wit…
Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Investor Relations - Laura HansenChief Executive Officer - Ryan WattsChief Commercial Officer - Katie PengChief Operating and Financial Officer -…
Denali Therapeutics DNLI reported a second-quarter 2026 loss of 68 cents per share, narrower than the Zacks Consensus Estimate of a loss of 73 cents. The company incurred a loss of 72 cents in the year-ago quarter. In late March, Denali se…
Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.72 per share a year ago. These figures are adjusted for non-recurring i…
Denali Therapeutics Inc. Strong first full quarter of AVLAYAH™ (tividenofusp alfa-eknm) launch generated $3.6 million in net product revenue Advanced TransportVehicle™ portfolio with two Alzheimer's disease programs now in clinical develop…
Denali Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it will report financial results and business highlights for the second quarter ended June…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Denali Therapeutics (DNLI) is scheduled to present at the Alzheimer's Association International Conference in London on…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Denali Therapeutics stock has delivered a 71.8% return over the past year, yet current valuation checks suggest the shares a…
By Daniella Parra VERAXA Biotech said it received positive scientific advice from Germany's Paul-Ehrlich-Institute supporting a preclinical development plan for its experimental BiTAC-TCE cancer therapy platform. The feedback provides grea…
By Daniella Parra Slate Medicines, a private biotech company developing new treatments for migraine and other headache disorders, has appointed Mark W. Hahn to its Board of Directors, they said. The company said Hahn brings more than 25 ye…
Denali Therapeutics, Inc. DNLI is developing innovative therapies for neurodegenerative diseases using its proprietary TransportVehicle platform, which is designed to help medicines cross the blood-brain barrier. The company is currently d…
Biogen will present detailed Phase 2 study data for its experimental Alzheimer’s drug diranersen at a conference in London. Continue Reading
Denali Therapeutics Inc. Denali co-founder and CEO Ryan Watts, Ph.D., to deliver opening plenary address at 2026 AAIC in London on July 12, 2026 Presentation will highlight recent scientific advances and future opportunities to accelerate…
Denali co-founder and CEO Ryan Watts, Ph.D., to deliver opening plenary address at 2026 AAIC in London on July 12, 2026Presentation will highlight recent scientific advances and future opportunities to accelerate discovery and development…
Regenxbio RGNX announced that it has reached alignment with the FDA on the next regulatory steps for the potential accelerated approval of Navsunli (clemidsogene lanparvovec-sngl, RGX-121), a one-time investigational gene therapy being dev…
Denali Therapeutics Inc. DNLI announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher ("PRV"). The sale will generate gross proceeds of $195 million. The PRV was granted to DNLI…
Denali Therapeutics Inc. Proceeds from transaction to support advancement of Denali's broad TransportVehicle™-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseases Denali was awarded Priority Review Vouc…
Proceeds from transaction to support advancement of Denali’s broad TransportVehicle™-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseasesDenali was awarded Priority Review Voucher following FDA approval…
By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) said it nominated ACU301 and ACU401, two candidates in its Enhanced Brain Delivery program, to treat Alzheimer's Disease. The nomination comes after the company exercised its optio…
Denali Therapeutics Inc. (NASDAQ:DNLI) is one of the 10 best AI driven biotech stocks to invest in. On May 22, Denali Therapeutics Inc. (NASDAQ:DNLI) halted its joint work with Biogen Inc. (NASDAQ:BIIB), around the development of BIIB122 f…
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Biogen and Denali Therapeutics have discontinued development of BIIB122 for early-stage Parkinson's…
We just covered the Jeff Bezos Stock Portfolio: Top 10 Stock Picks and Denali Therapeutics Inc. (NASDAQ:DNLI) ranks 10th on this list. Jeff Bezos established a strategic relationship with Denali Therapeutics Inc. (NASDAQ:DNLI) through his…
Denali Therapeutics' (DNLI) investors will now look at its other pipeline assets and broader platfor PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
The S&P 500 Index ($SPX) (SPY) on Friday closed up +0.37%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.58%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.42%. June E-mini S&P futures (ESM26) rose +0.35%, and June E-mi…
The S&P 500 Index ($SPX) (SPY) on Friday closed up +0.37%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.58%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.42%. June E-mini S&P futures (ESM26) rose +0.35%, and June E-mi…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Biogen and Denali Therapeutics halted development of experimental Parkinson's therapy BIIB122 after the Phase 2b LUMA s…
The S&P 500 Index ($SPX) (SPY) today is up +0.50%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.63%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.73%. June E-mini S&P futures (ESM26) are up +0.47%, and June E-mini Nasdaq futu…
Shares of Denali Therapeutics, Inc. DNLI were down 8% in after-market trading on May 21, after the company and partner Biogen BIIB announced disappointing top-line results from a mid-stage study evaluating BIIB122 (DNL151) in individuals w…
The S&P 500 Index ($SPX) (SPY) today is up +0.54%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.70%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.53%. June E-mini S&P futures (ESM26) are up +0.50%, and June E-mini Nasdaq futu…
(RTTNews) - Biogen (BIIB) and Denali Therapeutics' (DNLI) experimental Parkinson's disease treatment, BIIB122, did not meet its primary and secondary endpoints in the Phase 2b LUMA study, prompting the companies to discontinue its developm…
(RTTNews) - Biogen Inc. (BIIB) and Denali Therapeutics Inc. (DNLI) reported results from the Phase 2b LUMA study evaluating BIIB122 (DNL151), a small molecule inhibitor of LRRK2 in early-stage Parkinson's disease. The study found that BIIB…
Denali Therapeutics Inc. The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue development of BI…
Biogen Inc. The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue development of BIIB122 in idio…
The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue development of BIIB122 in idiopathic Parki…